Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus DERMA SMOOTHE FS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus DERMA SMOOTHE FS.
CAPEX vs DERMA-SMOOTHE/FS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid